

Marquette University
e-Publications@Marquette

Physics Faculty Research and Publications

Physics, Department of

10-1-2008

Role of the Zn₁ and Zn₂ Sites in Metallo- β -lactamase L1

Zhenxin Hu

Miami University - Oxford

Gopalraj Periyannan

Miami University - Oxford

Brian Bennett

Marquette University, brian.bennett@marquette.edu

Michael W. Crowder

Miami University - Oxford

Accepted version. *Journal of the American Chemical Society*, Vol. 130, No. 43 (October 2008):

14207-14216. DOI. © 2008 American Chemical Society. Used with permission.

Brian Bennett was affiliated with Medical College of Wisconsin at the time of publication.

Role of the Zn₁ and Zn₂ sites in Metallo-β-lactamase L1

Zhenxin Hu

*Department of Chemistry and Biochemistry, Miami University,
Oxford, OH*

Gopalraj Periyannan

*Department of Chemistry and Biochemistry, Miami University,
Oxford, OH*


Brian Bennett

*Department of Biophysics and National Biomedical EPR Center,
Medical College of Wisconsin,
Milwaukee, Wisconsin*

Michael W. Crowder

*Department of Chemistry and Biochemistry, Miami University,
Oxford, OH*

Abstract



In an effort to probe the role of the Zn(II) sites in metallo- β -lactamase L1, mononuclear metal ion containing and heterobimetallic analogues of the enzyme were generated and characterized using kinetic and spectroscopic studies. Mononuclear Zn(II)-containing L1, which binds Zn(II) in the consensus Zn₁ site, was shown to be slightly active; however, this enzyme did not stabilize a nitrocefim-derived reaction intermediate that had been previously detected. Mononuclear Co(II)- and Fe(III)-containing L1 were essentially inactive, and NMR and EPR studies suggest that these metal ions bind to the consensus Zn₂ site in L1. Heterobimetallic analogues (ZnCo and ZnFe) analogues of L1 were generated, and stopped-flow kinetic studies revealed that these enzymes rapidly hydrolyze nitrocefim and that there are large amounts of the reaction intermediate formed during the reaction. The heterobimetallic analogues were reacted with nitrocefim, and the reactions were rapidly freeze quenched. EPR studies on these samples demonstrate that Co(II) is 5-coordinate in the resting state, proceeds through a 4-coordinate species during the reaction, and is 5-coordinate in the enzyme-product complex. These studies demonstrate that the metal ion in the Zn₁ site is essential for catalysis in L1 and that the metal ion in the Zn₂ site is crucial for stabilization of the nitrocefim-derived reaction intermediate.

Introduction

β -Lactam-containing compounds are the most widely used antibiotics, and they exert their antimicrobial activity by inhibiting the cross-linking of the peptidoglycan building blocks of bacterial cell walls.¹ Ever since the introduction of these antibiotics in the clinic,

there has been an increasing number of bacterial strains that are resistant to these drugs. The most common way that bacteria become resistant to β -lactams is through the production of β -lactamases, which cleave the β -lactam bond and inactivate the drug.² There are 500 known β -lactamases, and these enzymes have been classified into four groups.³ Although groups A, C, and D exhibit different substrate specificities and susceptibilities to clinical inhibitors, they are similar in the fact that they utilize an active-site serine as a nucleophile to attack the β -lactam carbonyl, generating a tetrahedral intermediate.¹ The group B enzymes, on the other hand, require 1–2 Zn(II) ions to hydrolyze β -lactams and thus are called metallo- β -lactamases (M β ls).⁴ M β ls have been further categorized into three subgroups according to amino acid homology, substrate preference, and the number of Zn(II) ions required for full activity. The B1 subgroup, represented by CcrA, BcII, and IMP-1, have two metal binding sites: Zn₁, which consists of three histidines and a bridging hydroxide to coordinate Zn(II), and Zn₂, which consists of one histidine, one aspartate, one cysteine, the bridging hydroxide, and a terminally bound H₂O to coordinate Zn(II). The B2 enzymes, represented by CphA and ImiS, bind Zn(II) at the consensus Zn₂ site, which contains one histidine, one aspartate, one cysteine, and a solvent molecule to coordinate Zn(II). The B3 enzymes, represented by L1 and FEZ, bind two Zn(II) ions, contain the same Zn₁ site as the B1 enzymes, and utilize a Zn₂ site, which consists of two histidines, one aspartate, one terminally bound water, and the bridging hydroxide. Recently, a B2/B3 hybrid, metallo- β -lactamase GOB from *Elizabethkingia meningoseptica*, binds only 1 Zn(II) in the Zn₂ site.⁵

There exists considerable controversy about the metal content of the nominally dinuclear Zn(II)-containing (B1 and B3) M β l's. The initial crystal structure of BcII showed a single Zn(II) ion in the Zn₁ site of the enzyme;⁶ however, subsequent structures have shown a dinuclear Zn(II) site in BcII.^{7,8} Similar conflicting data on the metal content of L1, IMP-1, and CcrA have not been reported; however, Wommer et al. used *in vitro* binding assays to predict that all M β l's are metal-free *in vivo* and become mononuclear enzymes only in the presence of substrate.⁹ Wommer et al. continued by concluding that dinuclear Zn(II)-containing M β l's are isolation artifacts. Nonetheless, Page and co-workers have recently reported that BcII containing only

one equivalent of Co(II) is inactive, and the loss of metal ion during catalysis is the reason for the burst kinetics exhibited by this enzyme.¹⁰⁻¹² In contrast, Vila and co-workers have recently published that the BcII containing only one equivalent of Zn(II) is catalytically active^{13,14} and that B3 subgroup member, GOB, requires only a single metal ion in the Zn₂ to be active, analogous to the B2 enzymes.⁵

The metal ion binding characteristics of L1, CcrA, and BcII have been investigated and characterized.^{4,15} However, of much greater interest is the nature of the metal ion complement that is required for activity and the roles in catalysis, if any, of each of the metal ions that can be accommodated by these enzymes. The study of mononuclear or mixed-metal analogues of the enzymes provides one mechanism for the elucidation of the role of each metal and to indicate whether one or both are essential for activity. In addition, this information could be used to guide rational drug design efforts that use the Zn₁, Zn₂, or both sites as targets for inhibitors.

In this work, we describe the preparation and characterization of mononuclear metal ion- and mixed-metal-containing analogues of MβL1 from *Stenotrophomonas maltophilia*; kinetic, spectroscopic, and spectrokinetic analyses of these species reveal roles for both metal ions in catalysis.

Materials and Methods

Materials

Escherichia coli strains DH5α and BL21(DE3)pLysS were purchased from Gibco BRL (Gaithersburg, MD) and Novagen (Madison, WI), respectively. Plasmids pET26b(+) and pUC19 were purchased from Novagen. Restriction enzymes, *Nco*I and *Hind*III, deoxynucleotides (dNTPs), thermopol buffer, MgSO₄, and T4 DNA ligase were obtained from New England Biolabs (Beverly, MA), Promega Corporation (Madison, WI), and Gibco BRL. QuikChange site-directed mutagenesis kit was purchased from Stratagene. All mutagenic primers were purchased from Integrated DNA Technologies (IDT, Coralville, IA). Polymerase chain reaction (PCR) was performed using a Thermolyne Amplitron II from Barnstead (Dubuque, IA). DNA

purification was performed by using a Qiagen Quick Gel Extraction kit (Velencia, CA). The QIAGEN-tip 100 kit and protocols were used for large-scale plasmid purifications. A Wizard Plus Miniprep kit from Promega was used for small-scale plasmid DNA preparations. Luria–Bertani (LB) media was purchased from Invitrogen (Carlsbad, CA). Isopropyl- β -d-thiogalactoside (IPTG) was purchased from Anatrace (Maumee, OH). All buffer solutions were prepared using chemicals purchased from Fisher Scientific (Pittsburgh, PA). All buffers and growth media were made with Barnstead NANOpure, ultrapure water. For metal-free solutions, Chelex 100 resin (Biorad Laboratories, Hercules, CA) was used, and the resulting solutions were filtered through a 0.45- μ m filter membrane (Osmonic Inc.). Dialysis tubing was prepared as per Sambrook et al.¹⁶ from Spectro/Por regenerated cellulose, molecular porous membranes with a molecular weight cutoff of 10,000 Da (Spectrum Corporation, Gardena, CA). A fast protein liquid chromatography (FPLC) system, chromatography columns, and resins were purchased from GE Healthcare. Nitrocefin was obtained from Becton Dickinson Microbiology System (Cockeysville, MD), and solutions of nitrocefin were prepared as previously described.¹⁷

Generation of Histidine Mutants of L1 by Site-Directed Mutagenesis

The overexpression plasmids of four His \rightarrow Cys L1 mutants, H116C, H118C, H121C, and H196C were constructed using the L1 overexpression plasmid pET26b(+), which yields the full-length form of the enzyme, and the QuikChange site-directed mutagenesis kit as per the instructions of the manufacturer. The following primers were used to generate the mutants:

H116Cfor

CGGCTGATCCTGCTCAGCTGCGCACACGCCGACCATGCC

H116Crev

GGCATGGTCGGCGTGTGCGCAGCTGAGCAGGATCAGCCG

H118Cfor

ATCCTGCTCAGCCACGCATGCGCCGACCATGCCGGACCG

H118Crev

CGGTCCGGCATGGTCGGCGCATGCGTGGCTGAGCAGGAT

H121Cfor

CACGCACACGCCGACTGCGCCGGACCGGTGGCG

H121Crev

CGCCACCGGTCCGGCGCAGTCGGCGTGTGCGTG

H196Cfor

CACTTCATGGCGGGGTGCACCCCGGGCAGCACCGCG

H196Crev

CGCGGTGCTGCCCCGGGGTGCACCCCGCCATGAAGTG

H225Cfor

GTGTTGCTGACACCGTGCCCCGGGTGCCAGCAAC

H225Crev

GTTGCTGGCACCCGGGCACGGTGTCAGCAACAC

Overexpression of His→Cys Mutants

Large-scale preparations of His→Cys L1 mutants were conducted by using the procedure of Crowder et al.¹⁷ L1 was quantitated by monitoring the absorbance at 280 nm and using an extinction coefficient of 54,600 M⁻¹cm⁻¹.¹⁷

Preparation of 1Zn-, 1Co-, 1Fe-L1

Mature L1 (M-L1) was overexpressed as previously described by adding 100 μM ZnCl_2 , CoCl_2 , or $\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2$ to the minimal medium.¹⁸ After protein overexpression and centrifugation to collect the *E. coli* cells, the pellet was resuspended in 300 mL of 50 mM Hepes, pH 6.0, and the suspension was centrifuged for 15 min (8200g). The resulting pellet was resuspended in 50 mM Hepes, pH 6.0, and the cells were lysed by using a French press as previously described.¹⁷ The cleared supernatant (centrifugation for 25 min at 23,400g) was loaded onto a 25 mL SP-Sepharose column that was equilibrated with 50 mM Hepes, pH 6.0, and bound proteins were eluted from the column using a linear 0–500 mM NaCl gradient in the same buffer. L1 typically eluted at 80–120 mM NaCl, and the fractions were analyzed for the presence of L1 by using SDS-PAGE, as previously described.¹⁷

Preparation of ZnCoL1, ZnFeL1, FeFeL1, and CoCoL1 samples

The ZnFe analogue of L1 was prepared by adding 3 equiv of Zn(II) to as-isolated 1FeL1 or 3 equiv of Fe(II) to as-isolated 1ZnL1, followed by dialysis against 4 \times 1 L of Chelex-treated 50 mM Hepes, containing 50 mM NaCl, to remove unbound metal. The ZnCo analogue was prepared by adding 3 equiv of Zn(II) to 1CoL1. The FeFe and CoCo analogues of L1 were prepared by refolding apo-L1 in the presence of 100 μM Fe(II) or Co(II), as recently described.¹⁸

Metal Analyses

The metal content of the protein samples was determined by using a Varian Liberty 150 inductively coupled plasma spectrometer with atomic emission spectroscopy detection (ICP-AES). All the proteins were diluted to 10 μM with 50 mM Hepes, pH 7.0. A calibration curve with four standards and a correlation coefficient of greater than 0.999 was generated using Zn(II), Fe, and Co(II) reference solutions from Fisher Scientific. The following emission wavelengths were chosen to ensure the lowest detection limits

possible: Zn(II), 213.856 nm, Fe, 259.940 nm, and Co(II), 238.892 nm.

¹H NMR Spectroscopy

¹H NMR spectra were collected on a Bruker Avance 500 spectrometer operating at 500.13 MHz, 298 K, magnetic field of 11.7 T, recycle delay (AQ) of 41 ms, and sweep width of 400 ppm. Proton chemical shifts were calibrated by assigning the H₂O signal the value of 4.70 ppm. A modified presaturation pulse sequence (zgpr) was used to suppress the proton signals originating from solvent. The presaturation pulse was as short as possible (500 ms) to avoid saturation of solvent-exchangeable proton signals. The concentration of NMR samples was generally in the range of 1.0–1.2 mM. Samples in D₂O were prepared by performing three or more dilution/concentration cycles in a Centricon-10.

Rapid-Freeze-Quench (RFQ) and EPR Spectroscopy

L1 (0.5 mM) was reacted with 1.5 mM nitrocefin in 50 mM cacodylate buffer, pH 7.0, and at 3 ± 1 °C, and the reaction mixture was freeze-quenched for EPR spectroscopy using a system described in earlier work^{19,20} the calibrated reaction time was 10.4 ± 0.5 ms. Following EPR data collection, some samples were thawed by agitation of the sample tubes in water at 25 °C for 2 min and refrozen in liquid nitrogen. Low temperature EPR spectroscopy was carried out using a Bruker EleXsys E600 spectrometer equipped with an Oxford Instruments ITC503 liquid helium flow system. EPR was recorded at 9.63 GHz (**B**₀⊥**B**₁) or 9.37 GHz (**B**₀∥**B**₁) using an ER4116DM dual-mode cavity, with 100 kHz magnetic field modulation. Other EPR recording parameters are given in the legends to figures.

Steady-State Kinetics

All kinetic studies were conducted on a Agilent 8453 UV–vis diode array spectrophotometer at 25 °C. Steady-state kinetic parameters, the Michaelis constant K_m and the turnover number k_{cat} , were determined by monitoring product formation at 485 nm using nitrocefin as substrate in 50 mM Chelex-treated, cacodylate buffer, pH

7.0. The rate of change in the absorbance at 485 nm was converted into the rate of change in the concentration of the product by dividing the absorbance (path length = 1 cm) by the extinction coefficient of the product $17,420 \text{ M}^{-1} \text{ cm}^{-1}$.¹⁷

Stopped-Flow Kinetic Studies

Stopped-flow kinetic experiments were performed on an Applied Photophysics SX18MV spectrophotometer equipped with a constant-temperature circulating water bath as previously described.²¹⁻²³ All experiments were performed in 50 mM Chelex-treated, cacodylate buffer, pH 7.0, at 10 °C. All the proteins were diluted with 50 mM Chelex-treated, cacodylate buffer to 100 μM , and the substrate was prepared and diluted to 100 μM in the same buffer.

Results

Mutations of Metal Binding Histidines

Our previous attempts to prepare a mixed-metal analogue of L1 by adding Co(II) to apo- or 1Zn-L1 were unsuccessful primarily due to the oxidation of Co(II) to Co(III).²⁴ Another potential problem with generating a mixed-metal analogue is the reported dissociation constants for metal binding to the Zn₁ and Zn₂ sites in L1. Wommer et al. reported that the Zn(II) binding constants to the two sites in L1 are 2.6 and 6 nM.⁹ This result suggests that the addition of different metal ions to apo-L1 would result in sample with mixtures of possible metal centers. Therefore, we attempted to prepare a mixed-metal analogue of L1 by weakening one of the metal binding sites through mutation of one of the histidine groups in each metal binding site. For example, we reasoned that the mutation of His116 to Cys in the Zn₁ site would result in a mutant that binds the first added metal ion tightly to the Zn₂ site and the second metal ion much less tightly to the Zn₁ site.

Five metal binding mutants of L1 (H116C, H118C, H121C, H160C, and H263C) were successfully prepared using nondegenerate oligonucleotides, the QuikChange Site Directed Mutagenesis kit, and polymerase chain reaction. DNA sequencing of the resulting L1 genes in both directions was used to confirm that only the desired mutations

were present. Small-scale growth cultures showed that all five mutants were overexpressed at levels comparable to that of wild-type L1. However, large-scale (4 L) overexpression and purification of these mutants showed that only the H116C and H121C mutants were soluble and could be purified.

The purified mutants were analyzed for metal binding. After purification, the H116C mutant was shown to bind 0.33 equiv of Zn(II), while the H121C mutant bound 0.11 equiv of Zn(II) (Table 1). The mutants were incubated with a 10 fold excess of Zn(II), and the resulting enzymes were then exhaustively dialyzed versus Chelex-treated buffer. Zn(II)-loaded H116C and H121C mutants were shown to bind 0.85 and 0.98 equiv of Zn(II), respectively (Table 1), which is one-half of the metal bound by recombinant wild-type L1. The as-isolated and Zn(II)-loaded mutants were characterized by using steady-state kinetic studies. As-isolated H116C and H121C mutants exhibited k_{cat} values of $<0.01 \text{ s}^{-1}$ when using nitrocefin as substrate; however, the Zn(II)-loaded H116C and H121C mutants exhibited k_{cat} values of 0.38 and 2.3 s^{-1} and K_{m} values of 20 and $72 \mu\text{M}$, respectively. The inclusion of $100 \mu\text{M}$ Zn(II) in the steady-state kinetics assay buffer resulted in no change in the steady-state kinetic constants for the H116C mutant and a $k_{\text{cat}} = 33 \text{ s}^{-1}$ and a $K_{\text{m}} = 99 \mu\text{M}$ for the H121C mutant, when using nitrocefin as the substrate. While we were successful in preparing analogues of L1 with differential metal binding affinities for the Zn_1 and Zn_2 sites, one of the mutants exhibited very little activity (H116C), and the other exhibited a K_{m} value that suggested a large change in the active site of the enzyme (H121C).

Table 1. Steady-State Kinetic Parameters and Metal Content of HXXC Mutants of L1

mutant	$k_{\text{cat}}(\text{s}^{-1})$	$K_{\text{m}}(\mu\text{M})$	Zn(II)content
H116C ^a	<0.01	ND	0.33 ± 0.01
H121C ^a	<0.01	ND	0.11 ± 0.01
H116C ^b	0.38 ± 0.01	20 ± 1	0.85 ± 0.05
H121C ^b	2.3 ± 0.2	72 ± 25	0.98 ± 0.05
H116C ^c	0.35 ± 0.01	18 ± 1	NA
H121C ^c	33 ± 4	99 ± 15	NA
as-isolated/wild-type L1 ^c	41 ± 1	4 ± 1	1.90 ± 0.01

^aAs isolated.

^bAfter adding 2 equiv of Zn(II) and then dialysis.

°Reaction with 100 μM Zn(II) in buffer; ND - not determined; NA - not applicable.

Preparation and Characterization of the ZnCo-Analogue of L1

Our initial attempts to prepare Co(II)-substituted L1 by biological incorporation were unsuccessful because of the oxidation of Co(II) to Co(III) presumably during protein purification.²⁴ In these studies, the gene for L1 contained a leader sequence that directed the export of overexpressed L1 into the periplasm of *E. coli*, and our recent studies strongly suggest that folding and metalation of L1 occurs in the periplasm.¹⁸ In this same study, we demonstrated that the removal of the leader sequence from the L1 gene resulted in the enzyme being folded and metallated in the cytoplasm of *E. coli*. Significantly, the metal content of the resulting enzyme could be affected greatly by the addition of metal ions in the growth medium.

In an effort to prepare a Co(II)-substituted form of L1, we overexpressed L1 in minimal medium containing 100 μM CoCl_2 using the L1 gene without the leader sequence. The resulting, purified enzyme (called 1Co-L1) was pink, and the color did not change up to two months in 4 °C. Metal analyses revealed that the protein bound 0.9 equiv of cobalt and 0.1 equiv of Zn(II) (Table 2). Steady-state kinetic studies revealed that the enzyme exhibited a k_{cat} of $11 \pm 1 \text{ s}^{-1}$ and a K_{m} of $4.3 \pm 0.1 \mu\text{M}$, when using nitrocefin as a substrate (Table 2). These steady-state kinetic constants are different than those of ZnZn-L1 (k_{cat} of 39 s^{-1} ; K_{m} of $5.9 \mu\text{M}$); 1Zn-L1 (k_{cat} of 30 s^{-1} ; K_{m} of $5.5 \mu\text{M}$), and CoCo-L1 (k_{cat} of 63 s^{-1} ; K_{m} of $20 \mu\text{M}$) (Table 2). In addition, the k_{cat} values exhibited by the mononuclear metal ion containing analogues are not one-half of those exhibited by the dinuclear metal ion-containing analogues, suggesting that the samples of mononuclear metal ion-containing analogues are not made up of one-half dinuclear metal ion-containing analogues and one-half apo-enzymes.

Table 2. Steady state kinetics of different metal bound analogues of L1

species	$k_{\text{cat}}(\text{s}^{-1})$	$K_{\text{m}}(\mu\text{M})$	metal content
ZnZn-L1	39 ± 1	5.9 ± 0.5	2.0 ± 0.1 Zn(II) added
1Zn-L1	30 ± 1	5.5 ± 0.7	1.0 ± 0.1 Zn(II)
1Co-L1	11 ± 1	4.3 ± 0.1	0.9 ± 0.1 Co, 0.10 ± 0.01 Zn(II)
1Fe-L1	2.6 ± 1	53 ± 25	0.9 ± 0.1 Fe, 0.20 ± 0.01 Zn(II)

species	$k_{cat}(s^{-1})$	$K_m(\mu M)$	metal content
CoCo-L1 ^a	63 ± 3	20 ± 1	1.80 ± 0.20 Co
FeFe-L1 ^a	0	N/A	1.90 ± 0.01 Fe
ZnCo-L1	26 ± 0.3	2.3 ± 0.1	1.0 ± 0.1 Zn(II); 1.0 ± 0.1 Co
ZnFe-L1 ^b	20 ± 2	3.6 ± 1	1.0 ± 0.1 Zn(II); 1.0 ± 0.1 Fe
ZnFe-L1 ^c	24 ± 3	4.0 ± 1	1.2 ± 0.1 Zn(II); 0.9 ± 0.1 Fe

^aData from Hu et al.²⁶

^bFe added to Zn-L1 and then dialysis.

^cZn(II) added to Fe-L1 and then dialysis.

The UV-vis difference spectrum of 1Co-L1 revealed a broad, weak peak between 500–650 nm (Figure 1A), which was assigned to ligand field transitions of high-spin Co(II), and the extinction coefficient at 550 nm was $130 \text{ M}^{-1} \text{ cm}^{-1}$, which suggests that the Co(II) is 5-coordinate.²⁵ This spectrum is different than that of CoCo-L1, which was prepared by adding Co(II) to TCEP (tris(2-carboxyethyl)phosphine)-treated apo-L1, in that there is no broad absorbance peak between 330–360 nm corresponding to a S-to-Co(II) ligand-to-metal charge transfer band.²⁶ The addition of 1 equiv of Zn(II) to 1Co-L1 did not change the UV-vis spectrum (Figure 1A).




Figure 1. UV-vis and NMR spectra of 1Co-L1. (A) UV-vis difference spectrum of 1Co-L1 prepared using biological incorporation method. The enzyme concentration was 550 μM , and the buffer was 50 mM HEPES, pH 7.0. (B) ^1H NMR spectrum of 550 μM 1Co-L1. The asterisk signifies the peak that is solvent-exchangeable.

The ^1H NMR spectrum of 1Co-L1 showed one broad peak, which integrated to 2 protons, at 50 ppm, and the peak was solvent-

exchangeable (Figure 1C). Since there are two histidines in the Zn₂ site and three histidines in the Zn₁ site,²⁷ we assign these peaks to the NH protons on Co(II)-bound His121 and His263, which indicates the Co(II) is bound to the Zn₂ site in L1. The addition of 1 equiv of Zn(II) to 1Co-L1 did not change the NMR spectrum (Figure 1B).

Previously, we reported that 1Zn-L1 could be prepared by addition of 1 equiv of Zn(II) to apo-L1, and this sample was characterized with steady-state kinetics and EXAFS spectroscopy.²⁸ The enzyme exhibited a k_{cat} of 30 s⁻¹ and a K_m of 5.5 μM when using nitrocefin as the substrate (Table 2), but we were uncertain whether these constants reflected an enzyme sample that contained significant amount of ZnZn-L1 due to the amounts of adventitious Zn(II) found in buffers.^{9,29} The addition of Co(II) to 1Zn-L1 resulted in a pink coloration that immediately turned orange in less than 10 s, indicating oxidation of Co(II) to Co(III). On the other hand, the addition of Zn(II) to 1Co-L1, which was prepared by the biological incorporation method described above, resulted in a protein that remained pink in color. The ZnCo-L1 (this notation indicates Zn(II) in the Zn₁ site and Co(II) in the Zn₂ site) analogue of L1 exhibited a k_{cat} of 26 s⁻¹ and a K_m of 2.3 μM, when using nitrocefin as substrate. These values are similar to those of 1Zn-L1 and ZnZn-L1, and it is not possible with steady-state kinetics alone to determine if the ZnCo-L1 analogue is responsible for the observed activity.

EPR Spectroscopy of Metal-Ion-Substituted Forms of L1

EPR spectra of L1 with increasing Co(II) complement show a complex but sequential pattern of Co(II) binding (Figure 2A–E). A sample of nominally 1Co-L1 that was found to contain only 0.8 equiv Co(II) exhibited an EPR spectrum (Figure 2A) that contained two reasonably well-resolved components. A ⁵⁹Co hyperfine pattern with $A = 9.8 \times 10^{-3} \text{ cm}^{-1}$, centered at 996 G ($g_{\text{eff}} = 6.89$), and a derivative feature at 2320 G ($g_{\text{eff}} = 2.97$) were assigned to a rhombic species with $g_{\text{real}}(\perp) = 2.55$ and $E/D = 0.27$. The second species exhibited no sharp resonances and was due to an axial species similar to that observed from Co(II) in L1 in earlier work.²⁰ Based on previous reports, these signals are consistent with an equilibrium of Co(II)-H₂O and Co(II)-OH.³⁰⁻³² More typically, 1Co-L1 contained 0.9–1.0 equiv

Co(II), and the spectrum (Figure 2B) became less well-resolved, with only inflection points to suggest the presence of the distinct species observed at lower Co(II) complement. The spectrum of ZnCo-L1 (Figure 2C) was very similar to that of 1Co-L1 (Figure 2B), suggesting that the presence of Zn(II) in either of the binding sites did not significantly perturb the electronic structure of Co(II) in the remaining sites. In contrast, the spectrum of 2Co-L1 (Figure 2D) was markedly different from those of 1Co-L1 and ZnCo-L1; the spectrum could not be simulated assuming even two distinct species, and spin-Hamiltonian parameters could not be assigned. EPR absorption at very low field, 0–500 G, suggested the presence of a spin-coupled component in the spectrum, and this was confirmed by parallel mode EPR (Figure 2E), which revealed a resonance at $g_{\text{eff}} \approx 10$, consistent with $S' = 2$ and/or $S' = 3$ resonances in an $S' = 0, 1, 2, 3$ spin ladder due to coupling of two $S = 3/2$ Co(II) ions.




Figure 2. EPR spectra from metal-containing species of L1. Spectra are of the following species of L1: (A) L1 containing 0.8 equiv Co(II) at 12 K, 25 mW; (B) 1Co-L1 at 12 K, 2 mW; (C) ZnCo-L1 at 10 K, 2 mW; (D) CoCo-L1 at 12 K, 10 mW; (E) CoCo-L1 at 7 K, 20 mW, $\mathbf{B}_0 \parallel \mathbf{B}_1$; (F) 1Fe-L1 at 10 K, 2 mW; (G) ZnFe-L1 at 12 K, 10 mW; (H) FeFe-L1 at 10 K, 2 mW; (I) FeNi-L1 at 7 K, 50 mW; (J) FeCo-L1 at 10 K, 2 mW. Spectra are shown with arbitrary intensities.

Stopped-Flow Kinetic Studies on ZnCo-L1

The accurate interpretation of steady-state kinetic studies on mixed-metal and mononuclear metal-containing analogues can be complicated by the presence of adventitious Zn(II) in the assay buffers. For example, typical steady-state kinetic studies contain 1–10 nM L1, and the amount of adventitious Zn(II) in buffers, even those that have been Chelex-treated, can be between 10–100 nM.^{9,29} Therefore, it is probable that steady-state kinetic assays were conducted with enzymes containing a mixture of possible metal centers. Therefore, we characterized the mixed-metal analogues and proteins containing only one metal ion with presteady-state kinetic studies at or near single-turnover conditions ($\sim 50 \mu\text{M}$ enzyme and $\sim 50 \mu\text{M}$ nitrocefin). The advantage of this approach is that the enzyme concentrations in these samples are at least 2 orders of magnitude higher than the concentration of adventitious Zn(II) in the buffer. This approach also allowed us to monitor the role of each metal ion in catalysis.

1Zn-L1 was prepared as described above. The stopped-flow traces for 1Zn-L1 showed that substrate (absorbs at 390 nm) was depleted within 1.3 s (Figure 3A) and that very little intermediate (absorbs at 665 nm) was observed. The stopped-flow traces were fitted to an exponential equation, and the rate of product formation was $0.92 \pm 0.03 \text{ s}^{-1}$ (Table 3). In comparison, the stopped-flow trace of ZnZn-L1 showed that substrate was depleted in 0.06 s and that a significant amount of intermediate forms (Figure 3B). The rate of product formation was $17 \pm 1 \text{ s}^{-1}$ (Table 3), which reflects an 18-fold increase in activity as compared to that of 1Zn-L1. Previous EXAFS studies on L1 demonstrated that there is sequential binding of Zn(II) to apo-L1 and that the first equivalent of Zn(II) binds to the Zn₁ site.²⁸ This result coupled with the stopped-flow traces described above indicates that metal ions in both of the metal binding sites are required for the stabilization and observation of the reaction intermediate when nitrocefin is used as a substrate.




Figure 3. Stopped-flow traces of the reaction of Zn(II)-containing L1 analogues and nitrocefin. Stopped-flow traces of 50 μM 1Zn-L1 (A) and ZnZn-L1 (B) analogues when reacted with 50 μM nitrocefin at 4 $^{\circ}\text{C}$. The absorbance at 485 nm is due to the product, the absorbance at 390 nm is due to the substrate, and the absorbance at 665 nm is due to the intermediate.⁵⁴

Table 3. Exponential Fits to the Stopped-Flow Kinetic Data

species	rate of product formation (s^{-1}) ^a
1Zn-L1	0.92 ± 0.03
ZnZn-L1	17 ± 1
1Co-L1	0.05 ± 0.01
ZnCo-L1	12 ± 1
ZnFe-L1	12 ± 1
1Fe-L1	0.12 ± 0.02

^aRates determined by exponential fitting of the stopped-flow data in Figures 3, 4, and 7.

Stopped-flow studies were also conducted on the Co(II)-containing samples. The stopped-flow trace for 1Co-L1 showed that substrate decay took over 10 s and that no intermediate formed (Figure 4A). The rate of product formation was $0.05 \pm 0.01 \text{ s}^{-1}$ (Table 3). This result is not consistent with the steady-state kinetic results that showed that 1Co-L1 is very active (Table 2) and suggests that most of the activity observed in the steady-state kinetic studies was due to the ZnCo analogue of L1. The stopped-flow trace for ZnCo-L1 (Figure 4B) showed that substrate depleted as fast as it did for ZnZn-L1 (Figure 3B), and the rate of product formation was $12 \pm 1 \text{ s}^{-1}$ (Table 3), which reflects a 240-fold increase in activity over that of

1Co-L1. There is a 1.4-fold decrease in the amount of intermediate formed for ZnCo-L1, as compared to that for ZnZn-L1; however, there is a 1.4-fold increase in the amount of intermediate formed for ZnCo-L1 as compared to that for CoCo-L1 (Figure 5). The intermediate decays faster in the reaction with ZnZn-L1, as compared with CoCo- and ZnCo-L1, and the rates of intermediate decay for CoCo- and ZnCo-L1 are very similar. This result, along with the results described above, strongly indicates that cobalt binds to the Zn₂ site and that the Zn₂ site is involved in stabilizing the intermediate.




Figure 4. Stopped-flow traces of the reaction of Co(II)-containing L1 analogues with nitrocefin. 50 μ M 1Co- (A) and ZnCo-L1 (B) analogues were reacted with 50 μ M nitrocefin at 4 $^{\circ}$ C. The absorbance at 485 nm is due to the product, the absorbance at 390 nm is due to the substrate, and the absorbance at 665 nm is due to the intermediate.




Figure 5. Intermediate formation by L1 analogues. The absorbance at 665 nm arises from the presence of intermediate. Each reaction contained 50 μM L1 analogue and 50 μM nitrocefin at 4 $^{\circ}\text{C}$ in 50 mM cacodylate buffer, pH 7.0. (Inset) Intermediate formation for ZnZn-, ZnCo-, and CoCo-L1 analogues over 200 ms.

RFQ-EPR studies

EPR spectra recorded on ZnCo-L1 during an RFQ-EPR experiment are shown in Figure 6. The resting signals from ZnCo-L1 recorded at 10 K, 2 mW (Figure 6A) and at 7 K, 80 mW (Figure 6B) were very similar and are due to two isolated $S = 3/2$, $M_S = \pm 1/2$ systems. These systems are in turn due to Co(II) in either of the binding sites in singly occupied L1. Upon reaction with nitrocefin for 10 ms, the color of the sample became bright blue, and the EPR spectra shown in Figure 6C–E were observed. At 10 K, 2 mW (Figure 6C), the inflections in the spectrum (1600–2000 G), due to the presence of the isolated rhombic species of Figure 2A, were no longer observable, and instead a small but distinct sharp peak at 1025 G ($g_{\text{eff}} = 6.65$) was observed. At successively higher microwave power and lower temperature, this signal became more prominent as other features were lost to saturation and rapid-passage effects (Figure 6D, E), characteristic of an $M_S = \pm 3/2$ system and of tetrahedral Co(II). Upon further reaction, the sample turned red, indicating the hydrolysis of nitrocefin, and new EPR signals were observed (Figure 6F,G) that are presumably due to a product complex. These signals showed no evidence of an $M_S = \pm 3/2$ component but were unusual in that the g_z

feature at 2650 G ($g_{\text{eff}} = 2.6$) was very well-resolved, indicative of constrained geometry and consistent with binding of Co(II) to a more rigid ligand than water.³²




Figure 6. RFQ-EPR of ZnCo-L1 with nitrocefim. Spectra (A) and (B) are from resting ZnCo-L1. Spectra (C–E) are from ZnCo-L1 after reaction with nitrocefim for 10 ms at 3 °C. Spectra (F) and (G) are from ZnCo-L1 after incubation with nitrocefim for 2 min (at which time all of the added nitrocefim has been hydrolyzed). Spectra (A), (C) and (F) were recorded at 10 K, 2 mW, spectra (B), (D) and (G) at 7 K, 80 mW, and spectrum (E) at 5 K, 126 mW. Spectra are shown with arbitrary intensities.

Preparation and Characterization of the ZnFe-Analogue of L1

Our ability to prepare a mixed-metal analogue of L1 by using a biological incorporation method led us to speculate whether a ZnFe analogue of L1 could also be prepared. Recently, our studies using the overexpression plasmid that results in L1 being folded in the cytoplasm allowed us to prepare an iron-containing analogue of L1.¹⁸ However, the FeFe-L1 analogue was catalytically inactive. In an effort to prepare a ZnFe analogue of L1, we overexpressed L1 in minimal medium containing 100 μM Fe(II). The purified enzyme was green in color, contained 0.9 equiv of Fe and 0.23 of Zn(II), and exhibited a k_{cat} of 2.6 s^{-1} and a K_{m} of 53 μM , when using nitrocefim as the substrate. The addition of 0.8 equiv of Zn(II) resulted in a sample that exhibited a k_{cat} of 24 s^{-1} and a K_{m} of 4 μM (Table 2).

The EPR signal of 1Fe-L1 (Figure 2F) consisted of two types of signals. A rhombic $S = 5/2$ signal was observed with resonances at $g_{\text{eff}} \approx 9$ and ≈ 4.3 , and with some structure in the $g \approx 4.3$ region indicative of protein-bound Fe(III). The other contribution was from two very similar and largely overlapping signals with $g_{\text{eff}} < 2$ (3400–4000 G) and indicative of an antiferromagnetically coupled Fe(II)–Fe(III) dinuclear site.^{33,34} Spin quantitation³⁵ of these signals suggests that 50% of iron is from a mononuclear Fe(III) center, while 50% is from Fe(III)Fe(II) or Fe(II)Fe(III) centers. The amount of signal corresponding to Fe(III)Fe(II) (or Fe(II)Fe(III)) varied among samples, and the amount of the antiferromagnetically coupled centers was greatest in the sample corresponding to Figure 2F. More typically, we obtained spectra that contained only ~10% of the signal due to the spin-coupled center, perhaps due to oxidation of the center to the EPR-inactive Fe(III)Fe(III) center. Addition of Zn(II) generated ZnFe-L1, although the EPR signal varied from sample to sample. In all cases, there were small but reproducible changes in the Fe(III) signal (perhaps indicative of formation of an Zn(II)Fe(III) center in some molecules), and the intensity of the Fe(II)Fe(III) signal diminished, sometimes by a rather modest amount, as in Figure 2G, and sometimes almost completely. Spin quantitation³⁵ of the signals in Figure 2G were consistent with a 25–30% contribution from a spin-coupled center and a 70–75% contribution from Fe(III) in a single site. Further addition of iron, to form FeFe-L1, consistently abolished the Fe(II)Fe(III) signal (Figure 2H), as did additions of Ni(II) (Figure 2I) and Co(II) (Figure 2J). Additionally, marked changes in the Fe(III) signals in these bimetallic forms of L1 were observed. The $g \approx 9$ and 4.3 regions of the spectrum of FeFe-L1 differ from those of 1Fe-L1 and ZnFe-L1. Additional transitions were observed flanking the $g \approx 4.3$ region of the spectrum of FeNi-L1, indicating a narrowing of the distribution of E/D due to lowering of strain terms and a more constrained Fe(III) environment. The shape and intensity change of the $g \approx 9$ feature suggests changes in both strains and in D . In FeCo-L1, transitions due to Fe(III) and Co(II) in the region 800–3000 G could not be deconvoluted with confidence, but the very sharp nature of the $g \approx 4.3$ resonance from Fe(III) again indicates changes in the zero-field splitting parameters of Fe(III).

In an effort to further probe which site (Zn_1 or Zn_2) that the Fe binds, we attempted to obtain a 1H NMR spectrum of this sample; however, no peaks were observed between -200 to $+200$ ppm. We believe that the inability to observe any peaks in this sample is due, in part, to the relatively slow electron spin relaxation rate (T_{1e}) of high-spin Fe(III) and the large size (118 kDa) of L1, both of which result in significant broadening of 1H NMR peaks.³⁶ Our inability to observe paramagnetically shifted resonances due to the spin-coupled Fe(III)Fe(II) centers in the L1 samples is most likely due to the presence of a single bridging group (hydroxide) in this analogue and different relaxation properties as compared to similar centers in GLX2-5.³³

The ZnFe-analogue of L1 was also prepared by adding 1 equiv of Fe(II) directly to 1Zn-L1, which was made by adding 1 equiv of Zn(II) directly to apo-L1. This sample exhibited steady-state kinetic constants almost identical to those of the sample described above (Table 2). Similar to the results on cobalt-containing samples of L1, the 1Fe-L1 analogue exhibited little or no activity and produced no intermediate (Figure 7), suggesting the steady-state kinetic data for this enzyme were due to small amounts of ZnFe-L1. The rate of product formation for 1Fe-L1 was 0.12 ± 0.02 (Table 3). The stopped-flow traces for ZnFe-L1 showed substrate depletion occurred during the first 0.08 s and 2.6-fold less intermediate formed for this enzyme as compared to that for ZnZn-L1 (Figure 7). The rate of product formation for ZnFe-L1 (made by adding Zn(II) to 1Fe-L1 or by adding Fe(II) to 1Zn-L1) was 12 ± 1 , which reflects a 100-fold increase in activity as compared to that for 1Fe-L1 (Table 3).




Figure 7. Stopped-flow traces of Fe-containing L1 analogues reacted with nitrocefin; 50 μM 1Fe- (A), ZnFe-L1 (made by adding Fe(II) to 1Zn-L1) (B), and ZnFe-L1 (made by adding Zn(II) to 1Fe-L1) (C) were reacted with 50 μM nitrocefin at 4 $^{\circ}\text{C}$. The absorbance at 485 nm is due to the product, the absorbance at 390 nm is due to the substrate, and the absorbance at 665 nm is due to the intermediate.

RFQ-EPR Studies with FeZn-L1 and Nitrocefin

As with ZnCo-L1, the EPR spectrum of ZnFe-L1 was observed to change upon incubation with nitrocefin for 10 ms at 3 $^{\circ}\text{C}$ (Figure 8). The various transitions that make up the $g \approx 4.3$ line in ZnFe-L1 (Figure 8A) are due to the mean E/D being slightly less than $1/3$ and the strain-dependent distribution in E/D not being large enough to broaden out all of the transitions. Upon reaction with nitrocefin, the resonance positions of these partially resolved transitions change, indicative of a change in E/D and, hence, in the ligand field at Fe(III) (Figure 8B, G, H). Further change in the $g \approx 9$ resonance was observed (Figure 8C, D), and a shoulder was observed at $g \approx 5$ (1350 G Figure 8E, F) upon reaction of ZnFe-L1 with nitrocefin.




Figure 8. RFQ-EPR of ZnFe-L1 with nitrocefin. Trace A shows the 500–2500 G region of the spectrum of resting ZnFe-L1. Trace B shows the 500–2500 G region of the spectrum of ZnFe-L1 upon reaction with nitrocefin for 10 ms at 3 °C (solid line) overlaid with that of resting ZnFe-L1 (dashed line). The inserts show more detailed comparisons between the spectra over particular field ranges; traces (C), (F), and (G) are from resting ZnFe-L1, and traces (D), (E), and (H) are from ZnFe-L1 after reaction with nitrocefin for 10 ms at 4 °C.

Discussion

Zn(II) plays an essential catalytic role in enzymes from all of the major classes of enzymes and a structural role in a large number of other proteins.³⁷⁻³⁹ Due to its valence electronic configuration of [Ar]3d, Zn(II) is silent to most spectroscopic techniques. Fortunately, Zn(II) can be substituted with Co(II), and the resulting enzymes are catalytically active and contain metal binding sites nearly identical to those of the Zn(II)-containing analogues.^{32,40} For mononuclear Zn(II)-containing enzymes such as carbonic anhydrase, the Co(II)-substituted analogue yields unambiguous results regarding the function of the metal site in catalysis.⁴¹ However in the case of dinuclear Zn(II)-containing enzymes, the interpretation of kinetic/spectroscopic results are more complicated due to the presence of up to three distinct species, [M₁], [M₂] and [M₁M₂], that can interact with substrates in distinct ways and that can display overlapping spectroscopic signatures. Nonetheless, previous studies on dinuclear metal ion-containing aminopeptidase from *Aeromonas proteolytica* demonstrated that mixed-metal ion-containing analogues

of the enzyme could be used to probe the role of each metal in catalysis/binding.^{31,32,42} The metal binding mode of this enzyme is sequential, which allowed for the preparation and characterization of the ZnZn, ZnCo (or CoZn), 1Zn, and 1Co analogues. For other enzymes such as BcII, however, the binding constants of the two metal binding sites are similar, leading to mixtures of enzyme containing mononuclear, dinuclear, and even trinuclear metal ion-containing analogues.^{13,14} The interpretation of kinetic and spectroscopic results on such mixtures is difficult if not impossible to accomplish.

Since the metal binding K_{d1} and K_{d2} for Zn(II) binding to L1 was reported to be 2.6 and 6.0 nM,⁹ respectively, we did not initially believe that we could prepare enzyme samples containing 1Zn-, 1Co-, or ZnCo-centers by simply adding the metal ion to metal-free enzyme. Therefore, our first attempt to prepare these analogues involved the use of site-directed mutagenesis. The rationale for these studies was to introduce a mutation in one of the metal binding sites and to weaken metal binding to this site. Since Asp120 is essential for catalysis in L1,²³ we decided to substitute the metal binding histidines in the enzyme. Five site-directed mutants, with single point mutations, were generated; however surprisingly, only two of the resulting mutants were soluble. Fortunately, there was one HXXC mutation in each of the metal binding sites (H116C for Zn₁ site, H121C for Zn₂ site). Steady-state kinetic studies showed that the catalytic activities of both mutants were low (Table 1), which is consistent with the observed low Zn(II) incorporation. After incubation with excess Zn(II) and dialysis to remove loosely bound or nonbound Zn(II), both mutants were shown to bind nearly 1 equiv of Zn(II), which suggests that the one amino acid substitution did impair metal binding as expected. Steady-state kinetic studies conducted in the presence of 100 μ M Zn(II) demonstrated that H121C exhibits activity ($k_{cat} = 33 \pm 3 \text{ s}^{-1}$) similar to that of wild-type L1, although the mutant exhibited a much higher value for K_m . In contrast, the H116C mutant exhibited almost no activity even in the presence of added Zn(II). Since His161 is in the Zn₁ site, this result suggests that the Zn₁ site is important for catalysis; however, we cannot rule out the possibility that the point mutation did not alter the substrate binding site. These results also demonstrate that a mutation to one of the metal binding histidines

results in an enzyme that requires excess metal ion to saturate the mutated site. Since the excess metal ions would undoubtedly complicate subsequent spectroscopic analyses, we concluded that this strategy cannot be used to prepare the mixed-metal analogues of L1.

Consequently, we utilized a biological incorporation strategy in an attempt to prepare L1 analogues containing only one equivalent of Co(II) and the mixed metal ion-containing analogues. Overexpression of L1 in minimal medium containing cobalt resulted in an enzyme that binds ~0.9 equiv of Co(II). Spectroscopic studies strongly suggest that Co(II) is not delocalized between the two metal binding sites and that it binds to the consensus Zn₂ site (Figures 1 and 2). A similar metal content is obtained when L1 is overexpressed in the presence of Zn(II) using this same technique. Our previous EXAFS studies²⁸ and recent crystallographic studies by Dideberg⁴³ demonstrate that Zn(II) preferentially binds to the Zn₁ site. In agreement with the model of Co(II) binding to the Zn₂ site and Zn(II) binding to the Zn₁ site, the addition of 1 equiv of Zn(II) to 1Co-L1 results in an enzyme with EPR properties almost identical to those of 1Co-L1 (Figure 2B, C); however, the two analogues exhibit significantly different presteady-state kinetic behaviors (Figure 4). Surprisingly, a FeZn analogue of L1 can also be prepared by using the same strategy. EPR studies show that the resulting 1Fe-L1 contains a predominant ZnFe center; however, samples also sometimes contained some antiferromagnetically coupled Fe(III)Fe(II) (Figure 2G). The formation of a ZnFe center was reflected in differences between the Fe(III) EPR spectra of 1Fe-L1 and ZnFe-L1, and the narrowing of the spectrum upon incorporation of Zn(II) suggests increased conformational rigidity of the active site in the dimetallic form. While the effect of Zn(II) on the EPR signal was quite subtle, much more dramatic effects were observed with Ni(II) and Co(II). In both cases a significant reduction in the structural microheterogeneity of the Fe(III) environment was revealed by EPR, giving rise to resolved $E/D < 1/3$ transitions with Ni(II) and a very sharp $E/D = 1/3$ $g = 4.3$ line with Co(II). Interestingly, no spin-spin exchange coupling was detected in FeCo-L1. Both metal ions in L1 are required for maximum catalytic activity. Thus, the binding of the second metal ion fine-tunes the electronic structure of the first ion *via* a structural, rather than electronic, mechanism. We were unable to obtain ¹H NMR spectra of the Fe-containing analogues of L1 due to the

relatively slow T_{1e} of Fe(III)⁴⁴ and presumably due to the low concentration of Fe(II)Fe(III) in the sample. Nonetheless, we hypothesize that Fe(III) is binding to the Zn₂ site since the H–H–D motif is a common Fe(III) binding site in biology.⁴⁵ Fe(II) can bind at the Zn₁ site, but the addition of Zn(II) to 1Fe-L1 results in a reduction of the signal corresponding to the mixed-valent, dinuclear iron center (Figure 2G). The ZnFe analogue can be prepared either by adding Fe to 1Zn-L1 or Zn(II) to 1Fe-L1, since the resulting enzymes exhibit the same steady-state and presteady-state kinetic characteristics (Table 2 and Figure 7). Taken together, these results demonstrate that mixed-metal analogues of L1 can be generated and used in mechanistic studies to probe the role of each metal in catalysis.

Stopped-flow kinetic studies on 1Zn-, 1Co-, ZnZn-, and ZnCo-L1 were used to probe the role of the metal ions. 1Zn-L1, with Zn(II) in the Zn₁ site, exhibited some activity (ZnZn-L1 is 18-fold more active than 1Zn-L1, Table 3); however, very little intermediate was detected in these studies (Figure 3). On the other hand, 1Co-L1, with Co(II) in the Zn₂ site, is almost completely inactive (ZnZn-L1 is 340-fold more active than 1Co-L1, Table 3). It is likely that the small activity exhibited by 1Co-L1 in the stopped-flow studies (0.29% as compared to that by ZnZn-L1) is due to small amounts of Zn(II) in 1Co-L1 preparations (Table 1) and in the buffer (estimated to be 100 nM, which is 0.2% of the concentration of enzyme in the stopped-flow studies). The 1Fe-L1 analogue was >140-fold less active than ZnZn-L1 (Figures 4 and 7; Table 3), and this higher activity, as compared to that of 1Co-L1, is mostly due to the higher amounts of Zn(II) in the 1Fe-L1 samples (Table 2). We cannot unambiguously rule out that one of the Fe-containing analogues of L1 is active, although our studies indicate that FeFe-L1 is inactive (Table 2).¹⁸ These results indicate that both metal ions are required to detect intermediate in the reaction of nitrocefin with the ZnCo- and ZnFe-analogues of L1 (Figures 3, 4, 5, and 7). These results also indicate that an analogue of L1 with metal (Co(II) or Fe) only in the Zn₂ site is inactive. In contrast, an analogue of L1 with Zn(II) in the Zn₁ site does exhibit some activity, albeit very small (compare rates of product formation for 1Zn-L1 with those of 1Co-L1 and 1Fe-L1; Table 3), and this analogue does allow for the formation of a small (4%) amount of intermediate (Figure 3A). Taken together, these results demonstrate that both metal ions in L1 are

required for maximum catalytic activity. The Zn₁ site "prefers" Zn(II) over any other metal ion, and the role of this metal ion is presumably to provide the reactive nucleophile during catalysis. L1 analogues with metal ion only in the Zn₂ are not catalytically active. The Zn₂ site can bind a number of metal ions including Co(II) and Fe(III)/Fe(II). The role of this site is to stabilize the reaction intermediate during catalysis. This result is consistent with previous suggestions on CcrA⁴⁶ and on model complex-catalyzed hydrolysis of nitrocefin.^{47,48} It is not absolutely essential to have the Zn₂ filled in order that L1 be active since 1Zn-L1 does exhibit some catalytic activity. Based on previous studies on CcrA,^{46,49,50} the roles of the metal ions are most like the same in the subgroup 3A β -lactamase. The results presented above cannot necessarily be applied to BcII, since there is considerable controversy presently, regarding whether the mononuclear Zn(II)-containing enzyme is active.^{10,12-14} In addition, Vila and co-workers have reported that no ring-opened, nitrogen anionic intermediate is observed when BcII is reacted with nitrocefin.⁵¹

The successful preparation of a heterometallic analogue of L1 that contained a paramagnetic metal ion in one metal binding site allowed us to directly probe the reaction mechanism of L1 with RFQ EPR studies. The EPR spectrum of ZnCo-L1 was consistent with Co(II) being 5-coordinate in the resting form of the enzyme (Figure 6A and B). Within 10 ms reaction time, a 4-coordinate tetrahedral intermediate, not seen at all in any of the resting spectra from Co(II)-containing L1, was formed. This species decayed as substrate was exhausted, and a higher coordination product complex remained. This result confirms our previous work that showed that substrate, intermediate, and product coordinate the metal ion(s) in L1.²⁰ RFQ-EPR of ZnFe-L1 also showed catalytically competent changes in the EPR spectrum, here due to Fe(III).

On the basis of all of the data on L1 presented to date, we are in position to propose a reaction mechanism of nitrocefin hydrolysis by L1 (Figure 9). When nitrocefin binds, the terminally bound water molecule on Zn₂ releases, and the β -lactam carbonyl interacts with the metal ion in the Zn₁ site while the nitrogen lone pair on the nitrogen of the β -lactam interacts with Zn₂.^{27,52} The binding of substrate results in the loss of the Zn₂-bridging hydroxide bond, thereby generating a 4-

coordinate metal ion in the Zn₂ site and the reactive nucleophile that is directed for attack by Asp120.²³ The resulting, very short-lived tetrahedral species is converted to the ring-opened, nitrogen anionic intermediate after the loss of the β-lactam bond. At this time it is not clear if one metal ion or both are involved in the stabilization of the intermediate, but the data in this work clearly show that the metal ion in the Zn₂ site is essential for stabilization. The breakdown of the intermediate involves a protonation, which likely occurs during the concerted formation of a new bridging water/hydroxide. Our previous kinetic studies strongly suggested that Asp120 plays a role in orienting the acidic proton on the solvent molecule for protonation of intermediate.²³ When other substrates are used, there is evidence that the reaction intermediate does not accumulate,⁵³ suggesting that ring-opening and protonation of the β-lactam nitrogen is concerted. Regardless of substrate, the EP complex is in equilibrium with the resting enzyme, and in both cases, the coordination number at the Zn₂ site is 5.




Figure 9. Proposed reaction mechanism of L1 for the hydrolysis of nitrocefin.

The successful preparation of mononuclear metal ion-containing and heterometallic analogues of L1 has allowed us for the first time to probe the roles of the metal ions in this enzyme. It is clear that the metal ion in the Zn₁ site is essential for activity and that the most active form of the enzyme requires both metal ions. The metal ion in the Zn₂ site appears to be involved in the stabilization of a reaction

intermediate and possibly in orienting the β -lactam nitrogen for protonation. These results demonstrate that potential inhibitors can be designed to target the Zn₁ site only or both sites, although compounds that bind to the Zn₂ site and that block the Zn₁ site may also be effective inhibitors.

Acknowledgment

We thank the Volwiler Professorship (M.W.C.) and the National Institutes of Health (EB001980 and AI056231 to B.B.) for funding this work.

References

- ¹Fisher, J. F., Meroueh, S. O., and Mobashery, S. *Chem. Rev.* 2005, 105, 395– 424
- ²Perez, F., Endimiani, A., Hujer, K. M., and Bonomo, R. A. *Curr. Opin. Pharmacol.* 2007, 7, 459– 469
- ³Walsh, T. R., Toleman, M. A., Poirel, L., and Nordmann, P. *Clin. Microbiol. Rev.* 2005, 18, 306– 325
- ⁴Crowder, M. W., Spencer, J., and Vila, A. J. *Acc. Chem. Res.* 2006, 39, 721– 728
- ⁵Moran-Barrio, J., Gonzalez, J. M., Lisa, M. N., Costello, A. L., Dal Peraro, M., Carloni, P., Bennett, B., Tierney, D. L., Limansky, A. S., Viale, A. M., and Vila, A. J. *J. Biol. Chem.* 2007, 282, 18286– 18293
- ⁶Carfi, A., Pares, S., Duee, E., Galleni, M., Duez, C., Frere, J. M., and Dideberg, O. *EMBO J.* 1995, 14, 4914– 4921
- ⁷Fabiane, S. M., Sohi, M. K., Wan, T., Payne, D. J., Bateson, J. H., Mitchell, T., and Sutton, B. J. *Biochemistry* 1998, 37, 12404– 12411
- ⁸Davies, A. M., Rasia, R. M., Vila, A. J., Sutton, B. J., and Fabiane, S. M. *Biochemistry* 2005, 44, 4841– 4849
- ⁹Wommer, S., Rival, S., Heinz, U., Galleni, M., Frere, J. M., Franceschini, N., Amicosante, G., Rasmussen, B., Bauer, R., and Adolph, H. W. *J. Biol. Chem.* 2002, 277, 24142– 24147
- ¹⁰Badarau, A. and Page, M. I. *Biochemistry* 2006, 45, 11012– 11020
- ¹¹Badarau, A. and Page, M. I. *Biochemistry* 2006, 45, 10654– 10666
- ¹²Badarau, A., Damblon, C., and Page, M. I. *Biochem. J.* 2007, 401, 197– 203
- ¹³Llarrull, L. I., Tioni, M. F., Kowalski, J., Bennett, B., and Vila, A. J. *J. Biol. Chem.* 2007, 282, 30586– 30595
- ¹⁴Gonzalez, J. M., Medrano Martin, F. J., Costello, A. L., Tierney, D. L., and Vila, A. J. *J. Mol. Biol.* 2007, 373, 1141– 1156
- ¹⁵Heinz, U. and Adolph, H. W. *Cell. Mol. Life Sci.* 2004, 61, 2827– 2839

- ¹⁶Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*, 2nd ed.; Cold Spring Harbor Laboratory Press: Plainview, New York, 1989; Vol. 1.
- ¹⁷Crowder, M. W., Walsh, T. R., Banovic, L., Pettit, M., and Spencer, J. *Antimicrob. Agents Chemother.* 1998, 42, 921– 926
- ¹⁸Hu, Z., Gunasekera, T. S., Spadafora, L., Bennett, B., and Crowder, M. W. *Biochemistry* 2008, 47, 7947– 7953
- ¹⁹Sharma, N. P., Hajdin, C., Chandrasekar, S., Bennett, B., Yang, K. W., and Crowder, M. W. *Biochemistry* 2006, 45, 10729– 10738
- ²⁰Garrity, J. D., Bennett, B., and Crowder, M. W. *Biochemistry* 2005, 44, 1078– 1087
- ²¹Carenbauer, A. L., Garrity, J. A., Periyannan, G., Yates, R. B., and Crowder, M. W. *BMC Biochemistry* 2002, 3, 4– 10
- ²²Garrity, J. D., Paufl, J. M., and Crowder, M. W. *J. Biol. Chem.* 2004, 279, 39663– 39670
- ²³Garrity, J. D., Carenbauer, A. L., Herron, L. R., and Crowder, M. W. *J. Biol. Chem.* 2004, 279, 920– 927
- ²⁴Crowder, M. W., Yang, K. W., Carenbauer, A. L., Periyannan, G., Seifert, M. A., Rude, N. E., and Walsh, T. R. *J. Biol. Inorg. Chem.* 2001, 6, 91– 99
- ²⁵Garmer, D. R. and Krauss, M. *J. Am. Chem. Soc.* 1993, 115, 10247– 10257
- ²⁶Hu, Z., Periyannan, G. R., and Crowder, M. W. *Anal. Biochem.* 2008, 378, 177– 183
- ²⁷Ullah, J. H., Walsh, T. R., Taylor, I. A., Emery, D. C., Verma, C. S., Gamblin, S. J., and Spencer, J. *J. Mol. Biol.* 1998, 284, 125– 136
- ²⁸Costello, A., Periyannan, G., Yang, K. W., Crowder, M. W., and Tierney, D. L. *J. Biol. Inorg. Chem.* 2006, 11, 351– 358
- ²⁹Outten, C. E. and O'Halloran, T. V. *Science* 2001, 292 (5526) 2488– 2492
- ³⁰Bennett, B., Antholine, W. E., D'Souza, V. M., Chen, G. J., Ustinyuk, L., and Holz, R. C. *J. Am. Chem. Soc.* 2002, 124, 13025– 13034
- ³¹Bennett, B. and Holz, R. C. *Biochemistry* 1997, 36, 9837– 9846
- ³²Bennett, B. *Curr. Top. Biophys.* 2002, 26, 49– 57
- ³³Marasinghe, G. P. K., Sander, I. M., Bennett, B., Periyannan, G., Yang, K. W., Makaroff, C. A., and Crowder, M. W. *J. Biol. Chem.* 2005, 280, 40668– 40675
- ³⁴Schilling, O., Wenzel, N., Naylor, M., Vogel, A., Crowder, M., Makaroff, C., and Meyer-Klaucke, W. *Biochemistry* 2003, 42 (40) 11777– 11786
- ³⁵Bou-Abdallah, F. and Chasteen, N. D. *J. Biol. Inorg. Chem.* 2008, 13, 15– 24
- ³⁶Bertini, I., Turano, P., and Vila, A. *J. Chem. Rev.* 1993, 93, 2833– 2932
- ³⁷Auld, D. S. Zinc Catalysis in Metalloproteases. In *Metal Sites in Proteins and Models: Phosphatases, Lewis Acids, and Vanadium*; Hill, H. A. O., Sadler, P. J., and Thomson, A. J., Eds.; Springer-Verlag: New York, 1997; Vol. 89, pp 29– 50

- ³⁸Auld, D. S. *Biometals* 2001, 14, 271– 313
- ³⁹Auld, D. S. Cocatalytic zinc sites. In *Handbook of Metalloproteins*; Messerschmidt, A., Ed.; John Wiley & Sons: New York, 2004; Vol. 3, pp 416– 431
- ⁴⁰Bertini, I. and Luchinat, C. *Adv. Inorg. Biochem.* 1984, 6, 72– 111
- ⁴¹Bertini, I., Luchinat, C., and Scozzafava, A. *Struct. Bonding* (Ber.) 1982, 48, 45– 92
- ⁴²Bennett, B. and Holz, R. C. *J. Am. Chem. Soc.* 1997, 119, 1923– 1933
- ⁴³Nauton, L., Kahn, R., Garau, G., Hernandez, J. F., and Dideberg, O. *J. Mol. Biol.* 2008, 375, 257– 269
- ⁴⁴Bertini, I. and Luchinat, C. *NMR of Paramagnetic Molecules in Biological Systems*; Benjamin Cummings Publishing Company: Menlo Park, CA, 1986; p 317.
- ⁴⁵Hegg, E. L. and Que, L. *Eur. J. Biochem.* 1997, 250, 625– 629
- ⁴⁶Wang, Z., Fast, W., and Benkovic, S. J. *Biochemistry* 1999, 38, 10013– 10023
- ⁴⁷Kaminskaia, N. V., Spingler, B., and Lippard, S. J. *J. Am. Chem. Soc.* 2000, 122, 6411– 6422
- ⁴⁸Kaminskaia, N. V., Spingler, B., and Lippard, S. J. *J. Am. Chem. Soc.* 2001, 123, 6555– 6563
- ⁴⁹Wang, Z. and Benkovic, S. J. *J. Biol. Chem.* 1998, 273, 22402– 22408
- ⁵⁰Wang, Z., Fast, W., and Benkovic, S. J. *J. Am. Chem. Soc.* 1998, 120, 10788
- ⁵¹Rasia, R. M. and Vila, A. J. *ARKIVOC* 2003, 3, 507– 516
- ⁵²Spencer, J., Read, J., Sessions, R. B., Howell, S., Blackburn, G. M., and Gamblin, S. J. *J. Am. Chem. Soc.* 2005, 127, 14439– 14444
- ⁵³Spencer, J., Clark, A. R., and Walsh, T. R. *J. Biol. Chem.* 2001, 276, 33638– 33644
- ⁵⁴McMannus-Munoz, S. and Crowder, M. W. *Biochemistry* 1999, 38, 1547– 1553